A team of researchers at CIC Biogune unit cell biology and stem cells, together with a team of Paris Cardiovascular Research Center have developed a new area of research looks extremely promising for the development of new therapeutic responses to ischemic heart disease and cardiovascular diseases in general.By activating a protein called HIF, the strategy is to stimulate the revascularization and repair of damage due to organ ischemia caused by obstruction of a blood vessel prevents normal blood flow. These obstacles occur, for example, if a member of thrombosis, myocardial infarction or stroke. In this sense, it is important to note that cardiovascular disease is the leading cause of death worldwide .
These enzymes hydroxylate HIF and, as a result of this hydroxylation, the protein is degraded. Therefore, when the enzymes are inhibited, HIF is not degraded and accumulates as well. To inhibit a doctorate, using siRNA, said Dr.
The aim was to help stimulate the production of HIF after the femoral artery was artificially closed. And when they saw that they did this, the leg if not revascularized mouse entered a degenerative process.
How is this high level of HIF production? HIF is a protein that, when not required, degrades constitutively and this degradation is regulated by enzymes called doctorates.
Almost one in three adults in the United States have high blood pressure, but only about half of them are sufficient to control the condition of the drug, according to the CDC.